Q4 2025 Electromed Inc Earnings Call Transcript
Key Points
- Electromed Inc (ELMD) achieved record quarterly revenue of $17.4 million, marking a 17% year-over-year growth.
- The company reported a 30% increase in operating income for Q4, reaching $3 million, with improved operating leverage.
- Electromed Inc (ELMD) completed a $5 million stock repurchase program, demonstrating confidence in the company's future.
- The company's SmartVest therapy is gaining traction, with a significant campaign to raise awareness about bronchiectasis.
- Electromed Inc (ELMD) was recognized as the seventh fastest-growing public company in Minnesota by the Minneapolis/St. Paul Business Journal.
- The decrease in cash balance for fiscal year 2025 was driven by share repurchases and taxes paid from net share settlement of vested stock.
- The hospital market, while showing potential, has a longer sales cycle due to its nature as a capital equipment sale.
- There is a risk of tariff-related turbulence, although Electromed Inc (ELMD) is currently well-insulated.
- The introduction of new CRM systems could potentially impact sales force productivity during the transition period.
- The market for bronchiectasis treatment is still largely untapped, with many patients undiagnosed, posing a challenge for market penetration.
Good day, and welcome to the Electromed fourth-quarter fiscal year 2025 earnings conference call.
(Operator Instructions)
Please note, this event is being recorded.
I would now like to turn the conference over to Mike Cavanaugh, Investor Relations. Please go ahead.
Good afternoon, and thank you for joining the Electromed Earnings Call. Earlier today, Electromed, Inc. released financial results for the fourth-quarter and fiscal 2025. The press release is currently available on the company's website at smartvest.com.
Before we get started, I would like to remind everyone that some of the statements that management will make on this call are considered forward-looking statements including statements about the company's future operating and financial results and plans.
Such statements are subject to risks and uncertainties that could cause actual performance or achievements to be materially different from those projected. Any such statements represent management's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
